David M. Waterhouse
Experienced in Renal Vein Thrombosis

Dr. David M. Waterhouse

Hematology Oncology | Oncology
3301 Mercy Health Boulevard, Suite 100, 
Cincinnati, OH 
On Staff At
Accepting New Patients
Experienced in Renal Vein Thrombosis
3301 Mercy Health Boulevard, Suite 100, 
Cincinnati, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

David Waterhouse is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Waterhouse is rated as an Experienced provider by MediFind in the treatment of Renal Vein Thrombosis. His top areas of expertise are Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Pleuropulmonary Blastoma, and Colorectal Cancer. Dr. Waterhouse is currently accepting new patients.

His clinical research consists of co-authoring 74 peer reviewed articles and participating in 14 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
University Of Massachusetts Medical School, 1985
Residency
University Of Massachusetts Medical School, Internal Medicine, 1988
Specialties
Hematology Oncology
Oncology
Licenses
Internal Medicine in KY
Board Certifications
American Board Of Internal Medicine
Fellowships
University Of Michigan Medical School, Medical Oncology, 1991
Hospital Affiliations
Mercy Health - Anderson Hospital
Mercy Health - Fairfield Hospital
Mercy Health - Clermont Hospital
Mercy Health - West Hospital
The Jewish Hospital - Mercy Health
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Buckeye Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE-MEDICAID PLAN
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Community Health Choice
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Essence Healthcare
  • INSURANCE PLAN
  • MEDICARE MAPD
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medical Health
  • HMO
  • PPO
Medical Mutual
  • HMO
  • PPO
Ohio Health Group
  • PPO
Oscar
  • EPO
  • HMO
  • PPO
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 14 Less Insurance Carriers -

Locations

Oncology Hematology Care, Inc
3301 Mercy Health Boulevard, Suite 100, Cincinnati, OH 45211
Other Locations
Oncology Hematology Care, Inc
4350 Malsbary Road, Blue Ash, OH 45242

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

14 Clinical Trials

JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Erlotinib
Study Phase: Phase 3
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
A Phase 2 Study of Brentuximab Vedotin in Combination With Pembrolizumab in Participants With Metastatic Solid Malignancies
Enrollment Status: Active_not_recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drugs: Brentuximab vedotin, Pembrolizumab
Study Phase: Phase 2
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies
Enrollment Status: Active_not_recruiting
Publish Date: December 04, 2025
Intervention Type: Drug
Study Drug: Avelumab
Study Phase: Phase 3
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
A Randomized, Phase 2, Double-blind Study to Evaluate the Efficacy of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Metastatic Non-Squamous Non-Small Cell Lung Cancer
Enrollment Status: Terminated
Publish Date: August 08, 2025
Intervention Type: Drug
Study Drugs: Dostarlimab, Pembrolizumab, Chemotherapy
Study Phase: Phase 2
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy
Enrollment Status: Completed
Publish Date: June 25, 2024
Intervention Type: Drug
Study Drugs: Aldoxorubicin, Topotecan
Study Phase: Phase 2
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Trial of Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations (PROOF 302)
Enrollment Status: Terminated
Publish Date: March 13, 2024
Intervention Type: Drug
Study Drug: Infigratinib
Study Phase: Phase 3
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
A PHASE 1/1b MULTICENTER STUDY TO EVALUATE THE HUMANIZED ANTI-CD73 ANTIBODY, CPI-006, AS A SINGLE AGENT OR IN COMBINATION WITH CIFORADENANT, WITH PEMBROLIZUMAB, AND WITH CIFORADENANT PLUS PEMBROLIZUMAB IN ADULT SUBJECTS WITH ADVANCED CANCERS
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Drug
Study Drugs: CPI-006 Anti-CD73 Antibody, Ciforadenant, Pembrolizumab
Study Phase: Phase 1
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
A Phase 1b/2 Study of Viagenpumatucel-L (HS-110) in Combination With Multiple Treatment Regimens in Patients With Non-Small Cell Lung Cancer (The DURGA Trial)
Enrollment Status: Completed
Publish Date: September 21, 2023
Intervention Type: Biological, Drug
Study Drugs: Viagenpumatucel-L, Nivolumab, Pembrolizumab, Pemetrexed
Study Phase: Phase 1/Phase 2
The Circulating Cell-free Genome Atlas Study
The Circulating Cell-free Genome Atlas Study
Enrollment Status: Unknown
Publish Date: September 13, 2023
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes in Patients With Stage IV, 1L Non-Small Cell Lung Cancer to Determine Eligibility for the KEAPSAKE Clinical Trial (NCT04265534)
Enrollment Status: Terminated
Publish Date: March 13, 2023
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
A Phase 1/2 Study of Pegzilarginase (AEB1102, Co-ArgI-PEG) in Combination With Pembrolizumab in the Treatment of Patients With Extensive Disease (ED) Small Cell Lung Cancer (SCLC)
Enrollment Status: Completed
Publish Date: November 04, 2021
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
A Phase 3 Multicenter Open-label Study of Brigatinib (AP26113) Versus Crizotinib in Patients With ALK-positive Advanced Lung Cancer
Enrollment Status: Completed
Publish Date: August 20, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
A Phase II Study of the Combination of LY3023414 and Necitumumab After First-Line Chemotherapy for Metastatic Squamous Non-small Cell Carcinoma of the Lung
Enrollment Status: Terminated
Publish Date: December 09, 2020
Intervention Type: Drug
Study Phase: Phase 2
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer
Enrollment Status: Completed
Publish Date: February 01, 2019
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
View 13 Less Clinical Trials

73 Total Publications

Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Sotorasib versus docetaxel for previously treated KRAS G12C-mutated non-small-cell lung cancer: a plain language summary.
Journal: Future oncology (London, England)
Published: March 25, 2025
Similar Doctors
Kurt P. Leuenberger
Experienced in Renal Vein Thrombosis
Dr. Kurt P. Leuenberger
Hematology Oncology | Oncology
Experienced in Renal Vein Thrombosis
Dr. Kurt P. Leuenberger
Hematology Oncology | Oncology

Oncology Hematology Care, Inc

3301 Mercy Health Boulevard, Suite 100, 
Cincinnati, OH 
 (12.1 miles away)
888-649-4800
Languages Spoken:
English
See accepted insurances

Kurt Leuenberger is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Leuenberger is rated as a Distinguished provider by MediFind in the treatment of Renal Vein Thrombosis. His top areas of expertise are Lung Cancer, Pleuropulmonary Blastoma, Colorectal Cancer, Paget Disease of the Breast, and Bone Marrow Aspiration.

Evan Z. Lang
Experienced in Renal Vein Thrombosis
Dr. Evan Z. Lang
Hematology Oncology | Oncology
Experienced in Renal Vein Thrombosis
Dr. Evan Z. Lang
Hematology Oncology | Oncology

Oncology Hematology Care, Inc

3050 Mack Road, Suite 300, 
Fairfield, OH 
 (8.5 miles away)
888-649-4800
Languages Spoken:
English
See accepted insurances

Evan Lang is a Hematologist Oncology specialist and an Oncologist in Fairfield, Ohio. Dr. Lang is rated as a Distinguished provider by MediFind in the treatment of Renal Vein Thrombosis. His top areas of expertise are Plummer-Vinson Syndrome, Pleuropulmonary Blastoma, Lung Cancer, Familial Colorectal Cancer, and Bone Marrow Aspiration.

Benjamin T. Herms
Experienced in Renal Vein Thrombosis
Dr. Benjamin T. Herms
Hematology Oncology | Oncology
Experienced in Renal Vein Thrombosis
Dr. Benjamin T. Herms
Hematology Oncology | Oncology

Oncology Hematology Care, Inc

601 Ivy Gateway, Suite 1100, 
Cincinnati, OH 
 (11.8 miles away)
888-649-4800
Languages Spoken:
English
See accepted insurances

Benjamin Herms is a Hematologist Oncology specialist and an Oncologist in Cincinnati, Ohio. Dr. Herms is rated as a Distinguished provider by MediFind in the treatment of Renal Vein Thrombosis. His top areas of expertise are Colorectal Cancer, Familial Colorectal Cancer, Lung Cancer, Pleuropulmonary Blastoma, and Bone Marrow Aspiration.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Waterhouse's expertise for a condition
ConditionClose
View All 11 Distinguished Conditions
View All 45 Advanced Conditions
View All 145 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile